Single reversal trial of hydroxyurea (NSC-32065) in 91 patients with advanced cancer.
D000740:Anemia / Q000139:chemically induced; D001215:Asparaginase / Q000009:adverse effects; D001377:Azaserine / Q000009:adverse effects; D001943:Breast Neoplasms / Q000188:drug therapy; D002986:Clinical Trials as Topic; D003110:Colonic Neoplasms / Q000188:drug therapy; D004338:Drug Combinations; D006801:Humans; D006918:Hydroxyurea / Q000009:adverse effects / Q000627:therapeutic use*; D007970:Leukopenia / Q000139:chemically induced; D008175:Lung Neoplasms / Q000188:drug therapy; D008545:Melanoma / Q000188:drug therapy; D009369:Neoplasms / Q000188:drug therapy*; D012004:Rectal Neoplasms / Q000188:drug therapy; D012075:Remission, Spontaneous; D013237:Stereoisomerism; D013274:Stomach Neoplasms / Q000188:drug therapy; D013921:Thrombocytopenia / Q000139:chemically induced
D004338:Drug Combinations; D001377:Azaserine; D001215:Asparaginase; D006918:Hydroxyurea